Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about ...
Zacks Small Cap Research on MSN
BLRX: A Venture into GBM
BLRX READ THE FULL BLRX RESEARCH REPORT In a highly anticipated event, BioLineRx Ltd. (NASDAQ:BLRX) announced a deal to develop a new cancer drug in a joint venture with Hemispherian AS. Hemispherian ...
Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent ...
In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia ...
While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a ...
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ...
Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3 ...
Acetaminophen works via the brain’s endocannabinoid system to both reduce pain and induce changes that are beneficial for ...
Amphista Therapeutics discloses first details of its TEAD Targeted Glue program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback